Talk:Julphar/Archive 1

Arabic
If there is an article on this company in the Arabic-language Wikipedia, a link to that article should be added. Perhaps this article can be expanded from the Arabic one. Eastmain (talk • contribs) 12:52, 25 April 2012 (UTC)

Semi-protected edit request on 26 November 2014
Please change the current corporate logo, into our new corporate logo Http://www.julphar.net/images/julphar/logo.png

From the box on the top right corner, please change the Revenue from 1,024.1 Billion (2011) to 1.36 Billion (2013) the refrerence> http://www.julphar.net/annual_report

Please change the Operating Income from 200.0 Million (2011) to 235.84 Million (2013) http://www.julphar.net/annual_report

Please change the Net Income from 170.2 Million (2011) to 228.09 Million (2013) http://www.julphar.net/annual_report

Please change Employees from circa 1740 to more than 3000

From the Operations part, Please remove the paragraphs after the first one and replace it with: Julphar (Gulf Pharmaceutical Industries) is a UAE Company which manufactures and distributes Pharmaceutical Products, mainly in the Middle East and Africa Region. Based in the Northern Emirate of Ras Al Khaimah, Julphar was established in 1980 under the leadership of His Highness Sheikh Saqr Bin Mohammed Al Qasimi. It currently operates twelve manufacturing facilities globally and holds 3,483 product registration certificates. Eleven Facilities are based in Ras Al Khaimah in the United Arab Emirates and covers production areas including Tablets, Syrups and Suspensions. In 2013, Julphar launched its twelfth manufacturing facility in Addis Ababa, Ethiopia which produces tablets and syrups.

Julphar maintains a diverse product portfolio which target therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management.

In 2012 Julphar launched a $150m Manufacturing Facility entirely dedicated to producing Raw Material needed for Biosimilar products. This facility produces insulin crystals using r-DNA technology. Biosimilars are the more molecular-complex products, whose active substance is derived from a living organism by means of human recombinant DNA. Using human recombinant DNA technology to produce their own raw material means Julphar can provide its major markets - Middle East, Africa – with the API (Added Pharmaceutical Ingredient) needed to make insulin and erythropoietin.

In 2014, Julphar’s Diabetes Division announced an exclusive agreement with Dexcom, a global leader in glucose monitoring systems, to market the new device, Dexcom Platinum G4, in the Middle East region. It has already been approved by the US Food and Drug Association (FDA) as well as European Medicines Agency (EMA), and is currently available in the US, Canada, leading European countries, and Australia.

In 2014, Julphar announced that it has signed a five-year licensing deal with global healthcare provider MSD (Merck in the US and Canada). Under the agreement, Julphar will have exclusive rights to produce, market, distribute and sell certain MSD medicines in UAE, Kuwait, Bahrain, Oman, Qatar and Iraq. Julphar will manufacture some MSD products for the first time in this region, including therapies for diabetes, asthma, allergy, pain and inflammation.

Julphar employs approximately 3000 personnel around the world and registered sales revenue of AED 1.36 billion in the year ending 2013, up 15.4% year-on-year (yoy). Sales during the year were driven by the private market sales which saw a yoy growth of 19.4%.

Please add in images from our facility within the Operations part.


 * Http://www.julphar.net/uploads/photo/gallery/626x397/8.jpg Julphar Facility1


 * Http://www.julphar.net/uploads/photo/gallery/626x397/8.jpg Julphar Facility


 * http://www.julphar.net/uploads/photo/gallery/626x397/8.jpg
 * http://www.julphar.net/uploads/photo/gallery/626x397/8.jpg Julphar Facility

For the Subsidiaries part, please add
 * Julphar Ethiopia Facility (Ethiopia Plant)

For the Board of Directors, please Change Please change
 * Member of the Board (Sheikh Ahmed Bin Saqr Al Qasimi) to Member of the Board (Sheikh Abdullah Faisal Bin Saqr Al Qasimi)http://www.julphar.net/team
 * Member of the Board (Mohamed Jamaluddin Al Saati) to Member of the Board (Jamal Salem Bin Darwish Al Nuaimi) http://www.julphar.net/team

Jody.B.A (talk) 08:51, 26 November 2014 (UTC)
 * Yellow check.svg Partly done: I've updated the logo, the infobox stats, and the board of directors. As for the images of your facility, it must first be released under a compatible copyright license (by you). See here for instructions. Stickee (talk) 12:13, 26 November 2014 (UTC)

Semi-protected edit request on 30 November 2014
In Operations please add

In January 2013, Julphar launched its first international facility in Addis Ababa Ethiopia. This facility has the capacity to produce 25 million bottles, 50 million tablets and 170 million capsules per year.Annual Report 2013
 * Julphar Ethiopia

213.42.193.102 (talk) 05:18, 30 November 2014 (UTC)
 * Yes check.svg Done Stickee (talk) 07:03, 30 November 2014 (UTC)

Semi-protected edit request on 15 January 2015
Please add these images to this page. — Preceding unsigned comment added by Wikidori100 (talk • contribs) 04:57, 27 August 2015 (UTC)

https://commons.wikimedia.org/wiki/File:Julphar_Diabetes_Facility.jpg

https://commons.wikimedia.org/wiki/File:Diabetes_Facility.jpg

https://commons.wikimedia.org/wiki/File:Diabetes_Facility_1.jpg

https://commons.wikimedia.org/wiki/File:Manufacturing_Line.jpg

https://commons.wikimedia.org/wiki/File:Julphar_Diabetes_2.jpg

Julphar.uae (talk) 11:51, 15 January 2015 (UTC)
 * ❌: you have not made clear what you want done. Please clarify, in terms of "change X to Y" or "add X to the article" then either reopen the request or ping me.  G S Palmer (talk • contribs) 14:17, 15 January 2015 (UTC)

Semi-protected edit request on 25 March 2015
Please update the box with the following:

- Type: Privet Joint Stock Company

- Founded: 30, March 1980

- Products: Julphar manufacture and sell 213 products

- Revenue: 1.433 billion (2014) - Operating income: 238.5 million (2014) - Net income: 234.7 million (2014)

- Number of employees: 2900

- Slogan: Sustaining Health

This can be verified through our 2015 Fact Sheet,

- Please add the part below in the Operations segment.

Julphar Bangladesh Julphar has acquired a majority stake in Bangladesh-based RAK Pharmaceuticals, for a consideration of $9.5 million. The deal marks Julphar’s entry into the Bangladeshi market and is part of its expansion into Asia, the firm said. RAK Pharmaceuticals is a subsidiary of RAK Ceramics and produces a variety of industry compliant tablets, capsules and syrups. The company had sales worth $5.7 million in 2013, representing growth of 24 per cent year-on-year. Julphar and RAK Pharmaceuticals also have a joint partnership around technology transfer and commercial marketing agreement for advanced pharmaceutical products, the statement said. The latest deal will help Julphar tap into the $1.3 billion pharmaceuticals market in Bangladesh. “The size of the Bangladesh market alone provides huge investment opportunities, which can enhance the growing role of Julphar in the global healthcare industry,” said Ayman Sahli, CEO of Julphar. “RAK Pharmaceuticals is a relatively young, fresh company with solid infrastructure, growth rates and a healthy pipeline. “The stable investment outlook and the growing healthcare needs of a large, mostly under served population make Bangladesh an attractive market for investors. “Healthcare plays a major role in the expanding economy for Bangladesh and with this comes a clear need for increased manufacturing,” said Sahli. Julphar has been thriving in its home market due to burgeoning healthcare budgets and a growing population. The Emirati company has also expanded its manufacturing capabilities overseas, in an effort to tap into new markets. - Please change from Subsidiaries to UAE Manufacturing Facilities, because those facilities are wholly owned by Julphar and are within our premises in the Head Office & UAE for manufacturing. - Please add under this heading - Gulf Inject (Jebel Ali,Dubai).

- Please add this heading: Global Facilities Julphar Pharmaceuticals PLC (Ethiopia) RAK Pharmaceuticals (Bangladesh)

Julphar.uae (talk) 07:13, 25 March 2015 (UTC)
 * Red information icon with gradient background.svg Not done: Your edits seem promotional to me, and your username tells me that you have a strong connection to the subject of this article, and thus may have a conflict of interest. Consequently, I'm declining this request. Gparyani (talk) 04:32, 29 March 2015 (UTC)

Semi-protected edit request on 20 April 2015
Please update the box with the following:

- Type Privet Joint Stock Company

- Founded 30, March 1980

- Products Julphar manufacture and sell 213 products

- Revenue 1.433 billion (2014) - Operating income 238.5 million (2014) - Net income 234.7 million (2014)

- Number of employees 2900

- Slogan Sustaining Health

This can be verified through 2015 Fact Sheet, http://julphar.net/factsheet

- Please add the part below in the Operations segment. (This is the link to support it. http://julphar.net/news/details/98 )

Julphar Bangladesh Julphar has acquired a majority stake in Bangladesh-based RAK Pharmaceuticals, for a consideration of $9.5 million. The deal marks Julphar’s entry into the Bangladeshi market and is part of its expansion into Asia, the firm said. RAK Pharmaceuticals is a subsidiary of RAK Ceramics and produces a variety of industry compliant tablets, capsules and syrups. The company had sales worth $5.7 million in 2013, representing growth of 24 per cent year-on-year. Julphar and RAK Pharmaceuticals also have a joint partnership around technology transfer and commercial marketing agreement for advanced pharmaceutical products, the statement said. The latest deal will help Julphar tap into the $1.3 billion pharmaceuticals market in Bangladesh. “The size of the Bangladesh market alone provides huge investment opportunities, which can enhance the growing role of Julphar in the global healthcare industry,” said Ayman Sahli, CEO of Julphar. “RAK Pharmaceuticals is a relatively young, fresh company with solid infrastructure, growth rates and a healthy pipeline. “The stable investment outlook and the growing healthcare needs of a large, mostly under served population make Bangladesh an attractive market for investors. “Health Care plays a major role in the expanding economy for Bangladesh and with this comes a clear need for increased manufacturing,” said Sahli. Julphar has been thriving in its home market due to burgeoning healthcare budgets and a growing population. The Emirati company has also expanded its manufacturing capabilities overseas, in an effort to tap into new markets. With an eye on the African markets, Julphar launched its first international manufacturing facility in Ethiopia in 2013. It is also constructing a new facility in Saudi Arabia in partnership with local firm Cigalah Group. In 2012, Julphar also launched a $150 million manufacturing facility in the UAE, which produces the raw material needed for producing insulin.

- Please change from Subsidiaries to UAE Manufacturing Facilities, because those facilities are wholly owned by Julphar and are within their premises in the Head Office & UAE for manufacturing.

- Please add this heading: Global Facilities Julphar Pharmaceuticals PLC (Ethiopia) RAK Pharmaceuticals (Bangladesh)

Jody.B.A (talk) 10:54, 20 April 2015 (UTC)
 * Do you have a reference that says it is a "Private Join Stock Company"? Stickee (talk) 22:42, 20 April 2015 (UTC)

Semi-protected edit request on 26 May 2015
please change

- Revenue from AED 1.43 billion (2014) to AED 1.442,3 billion (2014) - Operating income from AED 238.5 million (2014) to AED 238.3 million (2014) - Net income from AED 234.7 million (2014) to AED 233.8 million (2014)

Jody.B.A (talk) 11:43, 28 May 2015 (UTC)
 * Red information icon with gradient background.svg Not done: as you have not cited reliable sources to back up your request, without which no information should be added to, or changed in, any article. - Arjayay (talk) 16:25, 28 May 2015 (UTC)

Semi-protected edit request on 23 August 2015
Please change the company type to a Privet Joint Stock Company.

Please edit In 2012, Julphar will become the only company, to In 2012, Julphar became the only company.

Please edit this sentence Julphar maintains a network of eleven manufacturing plants based in the UAE, with plans to open additional facilities in strategic countries such as Kingdom of Saudi Arabia, Ethiopia and Algeria. Please remove Ethiopia as its already established.

Please remove this sentence In 2011, Julphar crossed AED 1billion in sales, an 11.3% growth from 2010.[12].

Please add this sentence (updated financial results to replace the change earlier) In 2015 Julphar announced sales revenue worth AED 799.5 million in the first half of this year, with a growth of 5% compared to the same period of 2014. The company’s financial results, which were shared within the Board of Director’s report, showed a total profit of AED 497.8 million, up 9% yoy.http://www.julphar.net/news/details/117

Please move Julphar Ethiopia facility from UAE Manufacturing Facilities because its Ethiopia isnt in the UAE. Therefore please create Global Facilities subheading as they own two manufacturing facilities based on the fact sheet for 2015 http://www.julphar.net/factsheet 1. Julphar Pharmaceuticals PLC (Ethiopia) 2. RAK Pharmaceuticals (Bangladesh)

Julphar Bangladesh Julphar has acquired a majority stake in Bangladesh-based RAK Pharmaceuticals, for a consideration of $9.5 million. The deal marks Julphar’s entry into the Bangladeshi market and is part of its expansion into Asia. RAK Pharmaceuticals is a subsidiary of RAK Ceramics and produces a variety of industry compliant tablets, capsules and syrups. The company had sales worth $5.7 million in 2013, representing growth of 24 per cent year-on-year. Julphar and RAK Pharmaceuticals also have a joint partnership around technology transfer and commercial marketing agreement for advanced pharmaceutical products. http://www.julphar.net/news/details/98

Wikidori100 (talk) 09:57, 23 August 2015 (UTC)
 * Red information icon with gradient background.svg Not done: please establish a consensus for this alteration before using the template. Mdann52 (talk) 13:12, 31 August 2015 (UTC)

Semi-protected edit request on 21 January 2018
X

Julphar (Gulf Pharmaceutical Industries) is a public shareholding pharmaceutical company based in Diqdaqah, Ras Al Khaimah, United Arab Emirates. It was established in 1980 under Sheikh Saqr bin Mohammad al-Qassimi, the late ruler of Ras Al Khaimah and currently produces and distributes pharmaceutical products across five continents. Julphar produces therapeutic products which target a large range of pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology.

Y

Julphar (Gulf Pharmaceutical Industries) is one of the largest pharmaceutical manufacturers in the Middle East and Africa (MEA). Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qassimi in 1980, Julphar now employs more than 5,000 people and distributes pharmaceutical products to more than 50 countries across the globe.

Julphar’s business is centered around three core business units: Julphar Diabetes Solutions, General Medicines and Branded Generics and its consumer division, Julphar LIFE. The company's medicines target major therapeutic segments including Adult and Pediatric Primary Care, Gastro and Pain Management, Wound Management, Antibiotic, Cardiovascular and Metabolism.

Julphar has 16 internationally accredited facilities in Africa, the Middle East and Asia that produce more than a million boxes of medicines a day including tablets, syrups, suspensions, creams and injectables. In 2012, Julphar became one of the largest producers of Insulin with its UAE-based biotechnology production unit. Julphar123 (talk) 04:31, 21 January 2018 (UTC)
 * Red information icon with gradient background.svg Not done: as you have not cited reliable sources to back up your request, without which no information should be added to, or changed in, any article. - Arjayay (talk) 17:44, 21 January 2018 (UTC)

Semi-protected edit request on 21 January 2018
X

Key People

Sheikh Faisal bin Saqr Al Qasimi Chairman of the Board Dr. Ayman Ahmed Sahli CEO

Y

Key People

Sheikh Faisal Bin Saqr Al Qassimi, Chairman of the Board Jerome Carle, General Manager Julphar123 (talk) 04:35, 21 January 2018 (UTC)
 * Red information icon with gradient background.svg Not done: as you have not cited reliable sources to back up your request, without which no information should be added to, or changed in, any article. - Arjayay (talk) 17:45, 21 January 2018 (UTC)

Semi-protected edit request on 21 January 2018
X

Number of employees 2900

Y

Number of employees 5000 Julphar123 (talk) 04:36, 21 January 2018 (UTC)
 * Red information icon with gradient background.svg Not done: as you have not cited reliable sources to back up your request, without which no information should be added to, or changed in, any article. - Arjayay (talk) 17:46, 21 January 2018 (UTC)

Semi-protected edit request on 21 January 2018
X

Chairman of the Board (Sheikh Faisal Bin Saqr Al Qasimi) Vice-Chairman of the Board (Hassan Ahmed Al Alkim) Member of the Board (Sheikh Abdullah Faisal Bin Saqr Al Qasimi) Member of the Board (Sheikh Saqr Bin Humaid Al Qasimi) Member of the Board (Ahmed Essa Al Naem) Member of the Board (Nawaf Ghobash Ahmed Saeed) Member of the Board (Jamal Salem Bin Darwish Al Nuaimi) Member of the Board (Ali Hussein Al Zawawi) Member of the Board (Ahmed Salim Al Hosni) Chief Executive Officer (Ayman Ahmed Sahli)[15]

Y

Chairman of the Board (Sheikh Faisal Bin Saqr Al Qassimi) Vice-Chairman of the Board (Hassan Ahmed Al Alkim) Member of the Board (Sheikh Abdullah Faisal Bin Saqr Al Qassimi) Member of the Board (Sheikh Saqr Bin Humaid Al Qassimi) Member of the Board (Ahmed Essa Al Naem) Member of the Board (Nawaf Ghobash Ahmed Saeed) Member of the Board (Jamal Salem Bin Darwish Al Nuaimi) Member of the Board (Ali Hussein Al Zawawi) Member of the Board (Ahmed Salim Al Hosni) General Manager (Jerome Carle) Julphar123 (talk) 04:38, 21 January 2018 (UTC)
 * Red information icon with gradient background.svg Not done: as you have not cited reliable sources to back up your request, without which no information should be added to, or changed in, any article. - Arjayay (talk) 17:46, 21 January 2018 (UTC)